ETX-197 is under clinical development by ENSEM Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer). According to GlobalData, Phase I drugs for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ETX-197’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ETX-197 overview
ETX-197 is under development for the treatment of metastatic solid tumor, HR+/HER2- breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer (PROC), small cell lung cancer (SCLC) and unspecified indication. The drug candidate is administered through oral route. It acts by targeting cyclin-dependent kinase 2 (CDK2). The drug candidate is being developed based on Kinetic Ensemble platform.
ENSEM Therapeutics overview
ENSEM Therapeutics is a drug discovery and development company engaged in developing small molecule precision medicines for oncology with focus on genetic disorders and other diseases. The company is headquartered in Waltham, Massachusetts, the US.
For a complete picture of ETX-197’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
